Phase 2 Trial of Posdinemab Reveals Racial Differences in Screen Failure for Early Alzheimer Disease

New findings reveal racial disparities in Alzheimer’s trial eligibility, highlighting higher screen failure rates among Black participants in the Auτonomy study.:

Source: Neurology Read More

Previous PostPhase 2 Trial Data Support AR1001 as Potential Alzheimer Disease Monotherapy
Next PostEnhancing Digital Cognitive Assessment for Mild Cognitive Impairment With Acoustic Metrics: Tanya Talkar, PhD

Phase 2 Trial of Posdinemab Reveals Racial Differences in Screen Failure for Early Alzheimer Disease

Previous PostPhase 2 Trial Data Support AR1001 as Potential Alzheimer Disease Monotherapy

Next PostEnhancing Digital Cognitive Assessment for Mild Cognitive Impairment With Acoustic Metrics: Tanya Talkar, PhD

Related Posts

<![CDATA[Phase 3 Post Hoc Analysis Shows Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in Advanced Parkinson Disease ]]>

<![CDATA[DMD Management: Evolving Regimens and Real-World Adherence]]>

<![CDATA[NeuroVoices: Kate Rosenbluth, PhD, on Expanding Noninvasive Treatment for Essential Tremor With Cala kIQ Plus]]>

Categories